- 01A mouse injection versus a capsule
The endurance and fat-burning results come from mice given SLU-PP-332 by injection. Its own developers write that it lacks oral bioavailability, so a swallowed product is not what the research tested, before even asking whether mice predict people.
SLU-PP-332 is a small lab-made molecule, not a peptide, that switches on the estrogen-related receptors (ERRs), a family of proteins inside cells that turn on the genes muscle uses to adapt to endurance exercise. Its developers at Saint Louis University and Washington University tested it in muscle cells and in mice, where it raised fat burning and running endurance 1 2. That work is why it gets called an "exercise mimetic", a drug meant to copy some effects of exercise. Despite the name, ERRs do not respond to estrogen, and SLU-PP-332 is not a hormone.
What SLU-PP-332 is
Every cell has nuclear receptors, proteins that sit on DNA and switch groups of genes on or off. The three estrogen-related receptors are "orphan" receptors: no natural hormone that controls them has been found. They drive the genes for mitochondria (the parts of a cell that burn fuel for energy) and fat burning, and they are most active in hard-working tissues such as heart and muscle 5. Genetic studies had already shown that ERRs shape how well muscle copes with endurance work, but chemists had struggled to make a compound that switched on ERR-alpha 1.
SLU-PP-332 was the first that did so well enough to test in animals. It acts on all three ERRs and is most potent at ERR-alpha 1. A second compound from the same group, SLU-PP-915, has a different structure and was developed because SLU-PP-332 is poorly absorbed by mouth 4. Neither has been tested in people in any published study. Some of the authors hold shares in companies developing ERR drugs, which their papers declare 1 4.
What the studies found, and in what
All of the published evidence comes from cells and rodents. The table sets out each study, what was tested, and what it cannot tell you.
| Study | Tested in | Main finding | What it does not show |
|---|---|---|---|
| Billon et al., ACS Chemical Biology, 2023 1 | A muscle cell line; healthy mice | More mitochondrial activity in cells; more type IIa oxidative fibres and longer running endurance in mice | Any effect in people |
| Billon et al., J Pharmacol Exp Ther, 2024 2 | Diet-induced obese mice; ob/ob mice (bred to overeat) | Higher energy use and fat burning, less fat gain, better insulin sensitivity | Weight loss or blood sugar changes in humans |
| Xu, Billon et al., Circulation, 2024 3 | Mice with pressure-overload heart failure | Better pumping (ejection fraction), less scarring, longer survival | Any benefit for human heart failure |
| Billon et al., J Pharmacol Exp Ther, 2026 4 | Mice, comparing SLU-PP-332 with SLU-PP-915 | SLU-PP-332 lacks oral bioavailability; the newer compound works by mouth | That any swallowed form of SLU-PP-332 reaches muscle |
The mouse results are consistent across the group's papers: switching on ERR-alpha turned on an acute aerobic exercise gene program in muscle, and mice without working ERR-alpha did not gain the endurance boost 1. In the obesity study the authors summarise the effect as mimicking "exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation" 2. In the heart study, ERR-gamma, not ERR-alpha, did most of the protective work 3.
We previously developed an ERR pan-agonist, SLU-PP-332, which improves aerobic performance in mice but lacks oral bioavailability.
The distinction that matters: a mouse injection versus a capsule
The gap between the research and how SLU-PP-332 is sold online is wider than the usual "mice are not people" warning. In its lab studies the compound was given by injection, and the team that made it now states in print that it is poorly absorbed when swallowed 4. Products sold as SLU-PP-332 capsules or powders are therefore a route the published research did not support. Even if a product contained exactly what its label claims, there is no published evidence that enough would reach the muscle to do anything.
Is SLU-PP-332 safe?
Nobody knows, because it has never been tested in people. The papers report on endurance, fat and heart function in mice; they were not designed to find side effects, long-term harms, or interactions with medicines. ERRs act on genes in many tissues, including heart, liver, kidney and muscle 5, so effects outside muscle are plausible and unmeasured. The heart study also found that ERR activation turned down cell-growth genes in heart muscle cells 3, a reminder that switching on a gene program broadly has effects beyond the one you want.
Products sold as research chemicals add a second layer of risk: they are not regulated as medicines, so the contents and any contaminants are not checked. Anyone who has already taken a product like this and notices chest pain, a racing or irregular heartbeat, fainting, severe breathlessness, yellowing of the skin or eyes, or dark urine should get urgent medical care. For anything less urgent, tell your doctor exactly what you took so they can check your liver and kidney blood tests.
Legal and sport status
- Medicine: SLU-PP-332 is not approved as a drug in the US, the UK, the EU or elsewhere, and no company has published a human trial of it.
- Supplement: it is not a recognised dietary ingredient. In the US a dietary supplement can only contain dietary ingredients such as vitamins, minerals, herbs and amino acids, and the FDA does not approve supplements before sale 7.
- Sport: the World Anti-Doping Agency bans, at all times, any pharmacological substance not approved for human therapeutic use, and its list names metabolic modulators such as AMPK activators and PPAR-delta agonists 6. SLU-PP-332 falls under that ban, so a tested athlete who takes it risks a doping violation.
How it compares with exercise and with approved weight drugs
An exercise mimetic copies part of one signal. Exercise itself works on the heart, blood vessels, muscle, bone, brain and blood sugar at once, and decades of human trials back it. The obesity paper opens by noting that physical exercise is effective at reducing the risk of premature death from all causes 2, which is the benchmark any mimetic would have to approach. For weight, approved drugs such as semaglutide and tirzepatide have large human trials, known side effects and medical follow-up; experimental ones such as cagrilintide are at least in human trials. SLU-PP-332 has none of that.
| Regular aerobic exercise | Approved GLP-1 drugs | SLU-PP-332 | |
|---|---|---|---|
| Human evidence | Large trials and long-term studies | Large randomised trials | None published |
| Known side effects | Well described | Well described and monitored | Unknown |
| Product quality | Not applicable | Regulated medicine | Unregulated research chemical |
| Allowed in tested sport | Yes | Depends on the sport's rules | No 6 |
CalculatorVO2 max calculatorThe thing SLU-PP-332 tries to copy is aerobic fitness. This estimates yours, and it is a number training reliably moves.Work it out If you were looking at it for weight, blood sugar or endurance
The reasons people look up SLU-PP-332 (stubborn weight, creeping blood sugar, low stamina) usually show up first on a blood test, and that is where a useful plan starts. A fasting glucose or A1c drifting up, high triglycerides or a raised ALT (a liver enzyme that rises with fat in the liver) each point to a cause your clinician can act on. If your fasting glucose is already above range, the high fasting glucose page explains what it means and what is checked next, and the liver health page ranks what has human evidence for a fatty liver. Talk to your doctor before trying any untested compound, and bring these results to that conversation.
Markers to check before chasing an exercise mimetic
With human evidence for the same goals
For the wider picture of evidence-ranked options, see weight loss and body performance, and the guide to how to judge a supplement.
Citations
- Billon C, Sitaula S, Banerjee S, et al. Synthetic ERR alpha/beta/gamma agonist induces an ERR alpha-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756-771
- Billon C, Schoepke E, Avdagic A, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240
- Xu W, Billon C, Li H, et al. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024;149(3):227-250
- Billon C, Appourchaux K, Cote I, Burris TP. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787
- Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev. 2008;29(6):677-696
- World Anti-Doping Agency. The Prohibited List (S0 non-approved substances; S4 metabolic modulators)
- US Food and Drug Administration. Dietary supplements
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.









